-	My Health Newsletter™

-	My Health Reminders™

-	My Personal Health Reminders for Loved Ones™

-	My Baby Expectations™

-	My Health Links™

-	Medline Plus
-	Health Assessments

-	Allergy
-	Alternative Medicine
-	Alzheimer's Disease
-	Anxiety
-	Arthritis
-	Asthma
-	Blood Pressure
-	Brain Injury Rehabilitation
-	Breast Cancer
-	Cancer
-	Dental Care
-	Depression
-	Diabetes
-	Exercise / Fitness
-	Female Urological Disorders
-	Gastrointestinal Health
-	Healthy Diet
-	Heart Disease
-	Men's Health
-	Menopause
-	Neurology
-	Orthopedics
-	Parenting
-	Pregnancy
-	Rehabilitation
-	Senior Caregiving
-	Seniors' Health
-	Skin Health
-	Sleep Disorders
-	Spinal Cord Rehabilitation
-	Sports Medicine
-	Stroke Rehabilitation
-	Weight Management
-	Women's Health
-	Women's Heart Health

UserName:	Password:	Forgot Password?
Remember my username and password for future login.

FDA Approvals

Return to
Daily Health Main Page.

	Ella Emergency Contraceptive Approved

	Intended to inhibit or delay ovulation
	MONDAY, Aug. 16 (HealthDay News) -- The ella emergency contraceptive has been approved by the U.S. Food and Drug Administration. It's been available in Europe for more than a year under the brand name ellaOne. To be taken within five days of contraceptive failure or unprotected intercourse, the drug is not meant to be used as a routine contraceptive, the FDA said in news release. Among a class of drugs called progesterone agonists/antagonists, it's intended to inhibit or delay ovulation. Ella's safety and effectiveness were demonstrated in studies conducted in the United States, United Kingdom and Ireland, the agency said. The most common side effects included headache, nausea, abdominal pain, menstrual pain, fatigue and dizziness. Women with known or suspected pregnancy or those who are breast-feeding shouldn't use ella, the FDA said. The drug is distributed by Watson Pharma Inc., based in Morristown, N.J. More information The FDA has more about this approval.


	More FDA Approvals

	• Flu Vaccine for Upcoming Season Approved
	Protects against three strains predicted to be most prevalent

	• Cuvposa Approved for Chronic Drooling in Children
	Primarily those with neurological disorders

	• Combination Drug Approved for High Blood Pressure
	Tribenzor sanctioned for those who don't respond to other drugs

	• Generic Lovenox Approved for Deep Vein Thrombosis
	A condition that could cause deadly blood clots

Health Content Provided By:

The health content is provided for informational and educational purposes. It is intended for the general population and may not reflect specific conditions or risk of an individual or segment of the population. Therefore, it is not intended to be a substitute for professional medical advice, consultation, treatment or diagnosis. Always seek the advice of your physician or other qualified health provider with questions. Never disregard professional medical advice or delay in seeking it because of information obtained through these services.